Galapagos Stock Forecast, Price & News

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galapagos in the last year. There are currently 2 sell ratings, 10 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Galapagos stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLPG, but not buy additional shares or sell existing shares.
View analyst ratings for Galapagos or view top-rated stocks.

Wall Street analysts have given Galapagos a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Galapagos wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Galapagos saw a drop in short interest during the month of June. As of June 30th, there was short interest totaling 582,100 shares, a drop of 30.0% from the June 15th total of 831,000 shares. Based on an average daily volume of 247,300 shares, the days-to-cover ratio is presently 2.4 days. Approximately 0.9% of the shares of the stock are sold short.
View Galapagos' Short Interest.

Galapagos is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Galapagos.

Galapagos NV (NASDAQ:GLPG) announced its quarterly earnings data on Thursday, May, 6th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.71) by $1.47. The biotechnology company had revenue of $137.29 million for the quarter, compared to analyst estimates of $104.06 million. Galapagos had a negative trailing twelve-month return on equity of 10.05% and a negative net margin of 45.08%.
View Galapagos' earnings history.

Galapagos' stock was trading at $186.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GLPG stock has decreased by 67.5% and is now trading at $60.54.
View which stocks have been most impacted by COVID-19.

17 analysts have issued 1 year target prices for Galapagos' stock. Their forecasts range from $65.80 to $170.00. On average, they expect Galapagos' stock price to reach $125.78 in the next year. This suggests a possible upside of 107.8% from the stock's current price.
View analysts' price targets for Galapagos or view top-rated stocks among Wall Street analysts.

6 employees have rated Galapagos CEO Onno van de Stolpe on Glassdoor.com. Onno van de Stolpe has an approval rating of 100% among Galapagos' employees. This puts Onno van de Stolpe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Galapagos include BioMarin Pharmaceutical (BMRN), Zai Lab (ZLAB), Ono Pharmaceutical (OPHLF), Maravai LifeSciences (MRVI), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Dr. Reddy's Laboratories (RDY), Grifols (GRFS), Jazz Pharmaceuticals (JAZZ), CureVac (CVAC), Mirati Therapeutics (MRTX), Biohaven Pharmaceutical (BHVN), United Therapeutics (UTHR), BridgeBio Pharma (BBIO) and HUTCHMED (HCM).
View all of GLPG's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Galapagos investors own include Gilead Sciences (GILD), Celyad Oncology (CYAD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), argenx (ARGX), AbbVie (ABBV), Biogen (BIIB), Pharming Group (PHGUF), The Trade Desk (TTD) and Collegium Pharmaceutical (COLL).

(GLPG) raised $161 million in an IPO on Thursday, May 14th 2015. The company issued 3,800,000 shares at $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company served as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

Galapagos trades on the NASDAQ under the ticker symbol "GLPG."

Galapagos' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Cutler Group LP (0.00%), Henry James International Management Inc. (0.05%), Moody National Bank Trust Division (0.01%) and Atlas Capital Advisors LLC (0.00%).

GLPG stock was sold by a variety of institutional investors in the last quarter, including Moody National Bank Trust Division, and Henry James International Management Inc..

GLPG stock was purchased by a variety of institutional investors in the last quarter, including Cutler Group LP, and Atlas Capital Advisors LLC.

Shares of GLPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GLPG stock can currently be purchased for approximately $60.54.

Galapagos has a market capitalization of $3.97 billion and generates $605.66 million in revenue each year. The biotechnology company earns $-348,900,000.00 in net income (profit) each year or ($5.36) on an earnings per share basis.

Galapagos employs 1,304 workers across the globe.

The official website for Galapagos is www.glpg.com.

Galapagos is headquartered at GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800.

Galapagos' mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The biotechnology company can be reached via phone at (321) 534-2900 or via email at [email protected]